My laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine and eradication strategies. We have also applied our vaccine expertise to other infectious diseases of global significance such as Zika virus, tuberculosis, and most recently SARS-CoV-2. We received four NIH U19 Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program grants in 2005, 2008, 2012, and 2018 to construct adenovirus serotype 26 (Ad26) vectors, mosaic immunogens, and Env proteins and to evaluate these vaccine candidates in preclinical and clinical studies. Phase 2b and phase 3 clinical efficacy trials are underway with our mosaic Ad26/Env vaccine. We recently applied the Ad26 vector to the development of a SARS-CoV-2 vaccine, which is currently in global phase 3 clinical efficacy trials. We received two NIH U19/UM1 grants in 2011 and 2016 to establish consortia for innovative AIDS research (CIAR) in nonhuman primates and an NIH UM1 Martin Delaney Collaboratory (MDC) in 2016 to develop HIV-1 cure strategies. In addition, we received Gates Foundation consortium grants consortium grants to develop replicating adenovirus vectors, novel Env protein immunogens, broadly neutralizing antibodies, biomarkers for the viral reservoir, and animal models for SARS-CoV-2. My group is a key part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD) and the Ragon Institute of MGH, MIT, and Harvard. I currently serve as Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center and William Bosworth Castle Professor of Medicine and Professor of Immunology, Harvard Medical School.